Abbott Laboratories $ABT Stock Position Lifted by State Street Corp

State Street Corp boosted its stake in shares of Abbott Laboratories (NYSE:ABT) by 2.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 79,853,782 shares of the healthcare product maker’s stock after acquiring an additional 1,627,791 shares during the period. State Street Corp’s holdings in Abbott Laboratories were worth $10,004,880,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Harbor Capital Advisors Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at approximately $27,000. Intesa Sanpaolo Wealth Management purchased a new position in Abbott Laboratories during the fourth quarter valued at approximately $29,000. Bridge Generations Wealth Management LLC purchased a new position in Abbott Laboratories during the third quarter valued at approximately $33,000. Finally, Prudent Man Investment Management Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at approximately $33,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Abbott Laboratories Stock Performance

ABT stock opened at $87.89 on Friday. The firm has a 50 day moving average of $91.46 and a two-hundred day moving average of $107.98. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The company has a market capitalization of $153.08 billion, a price-to-earnings ratio of 24.62, a P/E/G ratio of 1.50 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the previous year, the company earned $1.09 earnings per share. Abbott Laboratories’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently commented on ABT. Evercore lowered their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. BTIG Research reissued a “buy” rating and issued a $131.00 target price on shares of Abbott Laboratories in a research report on Monday, April 27th. JPMorgan Chase & Co. decreased their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Bank of America decreased their target price on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Royal Bank Of Canada decreased their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $118.38.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.